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Abstract We evaluated six cases of diffuse large B-cell
lymphoma (DLBCL) involving the red pulp of the spleen.
All had B symptoms and an aggressive clinical course. The
lymphoma cells proliferated diffusely and non-cohesively
in the cords of the red pulp. The lymphoma involved the
bone marrow in four of the five patients and the liver in all
four of the patients examined. However, lymph node (LN)
involvement was rare at presentation, and systemic LN
involvement was not observed even in the terminal phase.
The lymphoma cells infiltrated the intrasinusoidal/intravas-
cular and interstitial spaces of the involved tissues and were
detected in the peripheral blood in two of the six patients.
CD5-expressing lymphoma cells were detected in four of
the five patients examined. Because these cases had some
unique clinical features and occurred in distinct splenic
sites, we proposed that primary splenic DLBCL manifest-
ing in red pulp is a distinct clinicopathological entity.
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Introduction
Extranodal diffuse large B-cell lymphomas (DLBCLs) have
specific clinicopathologic features that are dependent on the
organ of origin [1]. Primary splenic DLBCL is a rare type
of lymphoma. The majority of the DLBCLs are derived
from the white pulp of the spleen and form one large, or
multiple nodules [2]. Before the advent of immunohisto-
logical examination, the absence of mass formation and the
diffuse infiltration of large neoplastic cells into the red pulp
might have been diagnosed as malignant histiocytosis [3].
Kuratsune et al. [4] reported the first case of DLBCL that
non-cohesively proliferated into the splenic red pulp and
demonstrated clinicopathological features of malignant
histiocytosis. Since their initial report, only 18 cases of
DLBCLs non-cohesively infiltrating the splenic red pulp
have been reported [4–13]. These reports support the
existence of DLBCL manifesting in the splenic red pulp
(DLBCLRP). Kroft et al. [8] identified two cases of
DLBCLRP involving the bone marrow (BM) and the liver,
and Morice et al. [10] reported two cases of DLBCLRP
with prominent BM intravascular/intrasinusoidal lympho-
matous infiltration.
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Because there have been few case reports of DLBCLRP,
there is no comprehensive list of its clinicopathological
features. To clarify the features of this rare lymphoma, we
describe six new cases of DLBCLRP and present an
analysis of the clinicopathological features of an additional
18 previously reported cases [4–13]. After reviewing the
data, we developed seven characteristic features of
DLBCLRP. Based on these features, we propose that
DLBCLRP is a distinct clinicopathologic entity. Moreover,
we discuss the relationship between DLBCLRP and an
Asian variant of intravascular lymphomatosis (IVL) with
splenomegaly [14].
Materials and methods
Retrospective analyses were conducted for six patients
clinicopathologically diagnosed with primary splenic large
B-cell lymphoma manifesting in red pulp in our hospital
from 2000 to 2007. Two hundred and ninety two patients
were diagnosed with malignant lymphoma, including 228
with B-cell lymphomas (DLBCL 129, follicular lymphoma
58, marginal zone lymphoma 19, mantle cell lymphoma 6,
etc), 45 with T-cell lymphomas, and 12 with Hodgkin’s
lymphomas during this 8-year period. Thirteen patients
were diagnosed with primary splenic lymphoma, two with
splenic marginal zone lymphoma, one with follicular
lymphoma, and ten with DLBCL. Two patients were
diagnosed as having DLBCL with a micronodular pattern.
Eight patients were clinically diagnosed with DLBCLRP;
however, two were excluded based on the unavailability of
splenic tissues. All procedures were performed with
informed consent of the patients.
Tissue specimens obtained from surgery, biopsy, or
necropsy were fixed in formalin and embedded in paraffin.
The paraffin-embedded sections were dewaxed with xylene.
The sections were stained with hematoxylin–eosin (HE) for
light microscopic examination, and by the streptavidin–
biotin–peroxidase method (Nichirei Co., Tokyo, Japan) for
immunohistochemical analysis. The panel of primary anti-
bodies included L26 (CD20), JCB117 (CD79a), F7.2.38
(CD3), UCHL-1 (CD45RO), 1F8 (CD21), 124 (Bcl-2), PG-
B6p (Bcl-6), MIB-1 (Ki-67), MUM1p (MUM1), IgM
polyclonal (DAKO A/S, Glostrup, Denmark), MT1
(CD43), 4C7 (CD5), 56C6 (CD10), 1B12 (CD23), 1G12
(CD30), IgD polyclonal (Novocastra, Newcastle upon
Tyne, UK), and SP4 (Cyclin D1, Lab Vision, Fremont,
CA, USA). The primary antibodies were replaced with
mouse or rabbit serum as a negative control.
Epstein–Barr virus (EBV)-encoded RNA (EBER) was
detected by in situ hybridization (ISH). ISH was performed
using the BioGenex Automated Staining System (i6000;
BioGenex; San Ramon, CA, USA). The paraffin-embedded
sections were dewaxed with xylene, treated with proteinase
K, and hybridized with a fluorescein-conjugated oligonu-
cleotide EBER probe (PR005-10X, BioGenex). To visual-
ize the bound probe, a Super Sensitive polymer-HRP ISH
Detection System (DF300-YCX, BioGenex) was used
according to the manufacturer’s instructions.
Karyotypes were obtained at the time of diagnosis from all
six patients from spleen (n=5), and lymph node (LN; n=1)
samples, as previously described [15]. Chromosomal abnor-
malities were described according to ISCN [16].
Serum samples were analyzed with an immunofluores-
cence kit using anti-EBV capsid antigen (VCA), early
antigen, and EBV-encoded nuclear antigen (TFB Inc.,
Tokyo, Japan). Antibodies against the human immunodefi-
ciency virus (HIV) and HTLV-1 were examined using
chemiluminescent enzyme immunoassay kits (Abbot Japan
and Fuji Rebio Inc., Tokyo, Japan).
We characterized the degree of extramedullary hemato-
poiesis in the splenic samples as erythropoietic (grade 1),
granulopoietic (grade 2), and trilineage hematopoietic
(grade 3). Hemophagocytosis of normal splenic histiocytes
was characterized as grade 1 (<10) and grade 2 (>10)
erythrophagocytes in 10 high power fields. In bone marrow




In this series, five of the six patients were men (age, 64–
81 years; median, 69 years). At presentation, all patients
were febrile. Four patients (nos. 1, 3–5) had splenomegaly
without lymphadenopathy. One patient (no. 2) had
localized LN swelling at presentation and a second patient
(no. 6) had localized LN swelling at the time of surgery,
which suggested the presence of a primary splenic
lymphoma. All patients had high levels of lactate
dehydrogenase (LDH), soluble interleukin-2 receptor,
hypoalbuminemia, and moderately elevated C-reactive
protein (Table 1). Differential blood counts revealed the
following: Marked lymphocytopenia was detected in all
patients except 1 (no. 5), thrombocytopenia was detected
in five patients (nos. 1–5), and anemia was detected in
four patients (nos. 2, 4–6). In two patients (nos. 1 and 4),
lymphoma cells were detected in the peripheral blood
(Table 2). Cholestasis and hepatocellular damage with
hepatomegaly was observed in four patients (nos. 1, 2, 5,
and 6), suggesting hepatic involvement.
Characteristic clinical features of DLBCLRP (Table 2)
included BM involvement in four of the five patients (nos.
1, 2, 5, and 6; determined at admission), and hepatic
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infiltration in four patients (nos. 1, 5, and 6, and no. 2
determined at biopsy and necropsy, respectively). Enlarged
LN were rare and limited to localized areas. Systemic
lymphadenopathy was not observed even during the
terminal stage of the disease. Hemophagocytosis by normal
histiocytes was observed in the spleen and BM of all six
patients.
We assessed two treatment groups: (a) three patients
(nos. 2–4) were treated with six courses of CHOP
(combination of doxorubicin, vincristine, cyclophospha-
mide, and prednisolone), and (b) the remaining three
patients (nos. 1, 5, and 6) were treated with six courses of
rituximab and CHOP followed by two courses of rituximab,
etoposide, and nimustine hydrochloride with intrathecal
administration of methotrexate, Ara-C, and prednisolone
for prophylaxis of central nervous system lymphoma.
Follow-up (1–75 months; median, 38 months) information
was obtained for all six patients. Two patients (nos. 4 and 2) of
Table 1 Laboratory data, clinical stage, and international prognostic index upon admission
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Age (years)/sex 75 M 68 M 70 M 81 M 64 F 65 M
White blood cell count, ×109/L 2.4 3.9 7.6 7.4 2.3 2.9
Neutrophils, ×09/L 1.8 3.3 6.6 4.4 0.9 2.2
Lymphocytes, ×109/L 0.4 0.2 0.4 0.7 1.1 0.5
Hemoglobin level, g/L 140 116 133 100 87 91
Platelet count, ×109/L 40 83 99 116 38 137
LDH 1,045 4,312 1,822 2,690 460 404
ALP 842 1,677 228 193 2,102 1,168
γ-GTP 489 374 120 26 191 153
LAP 131 225 80 161 138
AST 217 380 55 67 51 49
ALT 34 211 37 11 36 58
CRP 165 122 105 93 58 25
TP 56 53 65 56 60 49
Albumin 27 26 30 29 28 25
sIL-2R 4,050 5,060 5,250 7,790 19,500 15,800
Ferritin 847 na 710 na 276 2,110
Hemophagocytosis in BMa + + + na + ++
Clinical stage 4B 4B 4B 4B 4B 4B
IPI H H H H H H
Abbreviation and normal level (in parentheses): M male, F female, ALP alkaline phosphatase (130–350 in cases 1, 4, 5, and 6; 66–220 in cases 2
and 3), LDH lactate dehydrogenase (80–200 in cases 1, 4, 5, and 6; 255–434 in cases 2 and 3), LAP leucin aminopeptidase (M 11–64, F 8–45),
AST aspirate aminotransferase (0–31), ALT alanine aminotransferase (0–41), CRP C-reactive protein (less 3 mg/L), sIL-2R soluble interleukin-2
receptor (220–530 U/mL), TP total protein (67–83 g/L), albumin (38–53 g/L), ferritin (M 27–320, F 3.4–89 ng/mL), BM bone marrow, na not
available, IPI international prognostic index, H high risk
a Grading of hemophagocytosis of normal histiocytes in bone marrow as grade + and ++ indicating thrombophagocytosis and leukoerythrophagocytosis
Table 2 Clinicopathological features of cases with primary splenic LBC lymphoma diffusely infiltrating the red pulp
Spleen Red pulp HPCa EMHb BM ISI II Liver ISI Portal Lymph node Blood
Weight Cord Sinus Splenic H Syst
Patient 1 75 M 525 + + ++ +++ + + + + + + − − 8%
Patient 2 68 M na +c +c + + + − + +c +c +c na Inguinal −
Patient 3 70 M 900 + + ++ + − − − na na na + − −
Patient 4 81 M 546 + + + + nd na na na na na − − 16%
Patient 5 64 F 675 + + + +++ + − + + + + + − −
Patient 6 65 M 220 + + + + + − + + + + − Abdominal −
ISI intrasinusoidal infiltration, II interstitial infiltration, HPC hemophagocytosis, EMH extramedullary hematopoiesis
a Grading of hemophagocytosis of normal histiocytes in spleens as + and ++ indicating less than ten and more than ten erythrophagocytes in 10
high power fields
b Grading of extramedullary hematopoiesis in spleens as +, ++, and +++ indicating erythropoiesis, granulopoiesis, and trilineage hematopoiesis,
respectively
c Necropsy
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the former group died of lymphoma, within 1 and 5 months of
the onset of the disease, respectively. All three patients of the
latter group survived following first complete remission.
All patients were negative for HIV and HTLV-1. Anti-
bodies to EBV indicated an old infection. M-protein and
autoantibodies, including Coombs’ test, were not detected
in any of the patients.
Pathologic features
Spleen size and weight were abnormally high in all
informative cases (nos. 1, 3, 4, 5, and 6). In one patient
(no. 2), spleen weight was not available (Table 2). The
weight of the spleen, which is 80 to 120 g in healthy
Japanese adults, was 220 to 900 g (median, 546 g) in the
patients. Cut surfaces of the spleens showed beef red color
and a lack of mass formation. In all six patients, the splenic
red pulp was expanded and diffusely infiltrated by non-
cohesive large lymphoma cells (nos. 1, 3, 4, 5, and 6 before
therapy, and no. 2 at necropsy). Lymphoma cells were
present in the cord and had infiltrated the sinuses to various
degrees (Fig. 1a–c). In one patient (no. 5), a small number
of large lymphoma cells were scattered among numerous T
cells/histiocytes, and the patient was diagnosed with T-cell/
histiocyte-rich B-cell lymphoma. All patients had extra-
medullary hematopoiesis of erythroblasts. Trilineage extra-
medullary hematopoiesis was observed in two patients (nos.
1 and 5). In all six patients, there were an abnormally high
number of histiocytes, which were engaged in hemopha-
gocytosis. In two (nos. 1 and 3) of these patients, there was
intensive hemophagocytosis.
In one patient (no. 1), CD20 and CD34 immunohis-
tochemistry revealed large lymphoma cells that were
visible in the sinusoids and a few were present in the
cords (Fig. 2a,b). In the remaining patients, the lymphoma
cells had diffusely infiltrated the interstitial spaces
(Fig. 2e). It is possible that the intravascular lymphoma-
tous infiltration of this lymphoma disappeared due to the
destruction of endothelial cells by lymphoma cells in the
significantly infiltrated lesions. Thrombophagocytosis in
the BM was observed in all patients, and leukoerythro-
phagocytosis was detected in one of the five patients
examined (no. 6).
In four patients examined (nos. 1, 5, and 6 at biopsy, and
no. 2 at necropsy), lymphoma cells had infiltrated into the
sinusoidal and portal areas of the liver (Fig. 2c).
In one patient (no. 2), the lymph nodes were replaced
completely by lymphoma cells. Intravascular infiltration of
lymphoma cells was not visible in the HE-stained samples.
However, diffuse infiltration into the vascular spaces was
clearly detected by immunostaining for CD34 (Fig. 2d).
Furthermore, in one patient (no. 4), intravascular infiltration
of lymphoma cells was prominent in the adipose tissue of
the splenic hilus (Fig. 2f), and in another patient (no. 1)
infiltration into the subcutaneous vessels was observed. In
three patients (nos. 2–4), lymphoma cells had infiltrated
below the endothelial cells or into the vascular wall
(Fig. 1d).
Immunohistochemistry of lymphoma cells
All patients had lymphoma cells positive for CD20 and
Bcl-2 and negative for EBER, Cyclin D1, and CD23
(Table 3). The cells in two patients (nos. 3 and 6) were
positive for CD10. Of the remaining four patients with
CD10-negative lymphoma cells, the cells were negative for
bcl-6 in three patients (nos.1, 4, and 5), and positive for bcl-
6 and MUM1 in one patient (no. 2). CD5-positive cells
were found in four of five patients by flow cytometry and
three of five patients by immunohistochemistry. Cells of
five patients examined were positive for surface membrane
(sm) IgM and negative for smIgD (Table 3). Positive rate of
Ki67 varied from 10% to 80%.
Chromosomal analysis
Chromosomes were analyzed in all six patients. Two
patients (nos. 5 and 6) had normal karyotypes. The
remaining four patients (nos. 1–4) were CD5-positive and
carried complex chromosomal aberrations. One of these
patients (no. 4) showed the 11q13 aberrations, whereas
another (no. 2) showed the 3q27 abnormality (Table 4).
Discussion
Here, we have reported six cases of DLBCLRP. To further
clarify the clinicopathological characteristics of DLBCLRP,
we analyzed a total of 24 cases (Tables 5 and 6) of
DLBCLRP, including six cases encountered by one of the
authors (M. Kashimura). In the present series, 18 of the 24
patients were men and the age range of all the patients was
40–81 years (median, 64.5 years).
The size and weight of the spleens that were examined
had increased in all informative cases. Spleen weight
data were not available for five of the 24 patients. The
weight of the spleen, which is 80–120 g and 110–170 g in
healthy adults of Japan and western countries, respective-
ly, was 220 to 2,600 g (median, 1,300 g) in the present
cases.
We found that DLBCLRP has seven characteristic
clinicopathological features as shown in Table 7 and a
pattern of infiltration of the spleen. Lymphoma cells were
present in the cord in all but one case of the 24 cases of
splenic infiltration. In the remaining patient, the lymphoma
cells were restricted to the sinusoids [7].
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At presentation, lymphoma cells were frequently found
in the BM (13/20, 65%) and the liver (11/17, 65%).
However, LN involvement was rare and limited to a
localized area (10/21, 48%), and LN swelling was not
significant. Systemic LN swelling was not observed, even
during the terminal phase of the disease.
Another characteristic of DLBCLRP is an intrasinusoidal
infiltration of lymphoma cells in the BM (3/7, 43%) and the
liver (8/8, 100%) as well as interstitial infiltration of
lymphoma cells in the BM (10/11, 91%) and the liver (7/8,
88%). Furthermore, we observed intravascular infiltration of
lymphoma cells in the LN (no. 2) and the adipose tissue
(nos. 1 and 4), and the presence of lymphoma cells in the
peripheral blood (10/23, 43%). This rate appears higher than
that observed for nodal DLBCL.
Moreover, we observed lymphoma cell surface expres-
sion of the CD5 antigen in eight of the ten patients (80%)
[8, 10, 12], including four of our original six patients. Low
intensity of the lymphoma cell CD5 antigen might not be
detectable by immunohistochemistry (Tables 3 and 6).
None of the patients had a history of chronic lympho-
cytic leukemia. Transformation of splenic marginal zone
lymphoma (SMZL) into DLBCL [17, 18], which might be
associated with CD5-positive transformation, must be ruled
out in order to diagnose DLBCLRP as the de novo
DLBCL. Despite a careful study, we were unable to find
proliferative lesions of medium-sized lymphoma cells in
any of our cases, which is usually observed when DLBCL
transforms from SMZL. Lymphoma cells of all five patients
examined were positive for smIgM; however, they were
Fig. 1 Lymphoma cells infiltrate the Billroth’s cords and sinuses of
the splenic red pulp and the vascular wall. a Medium power field of
the affected spleen. The tumor cells have diffusely infiltrated the
Billroth’s cords of red pulp, case 3 HE staining. Original magnifica-
tion, ×100. b Medium power field of the affected spleen. Tumor cells
have diffusely infiltrated the Billroth’s cords as well as the sinusoid,
case 4 HE staining. Original magnification, ×100. c High power
magnification of PAS-stained sections showing the basement mem-
brane of the sinusoid. Note the intrasinusoidal and extrasinusoidal
lymphoma cell infiltrations, case 1. Original magnification, ×350. d
Monomorphous lymphoma cell infiltration in the vascular wall. Short
arrows indicate the vascular endothelial cells and long arrows indicate
the arterial adventitia. Case 3 HE staining. Original magnification, ×40
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Fig. 2 Intrasinusoidal/intravascular lymphoma cell infiltration in the
bone marrow, liver, lymph node, and adipose tissue. a CD20 immunos-
taining showing the predominantly intrasinusoidal pattern of marrow
infiltration by large B-cell lymphoma, case 1. Original magnification,
×450. b CD34 immunoperoxidase staining of bone marrow sinusoidal
cell lining (arrow). Large lymphoma cells are present in a sinus, case 1.
Original magnification, ×350. c High power field of affected liver. Note
an intrasinusoidal infiltration of large lymphoma cells, case 1 HE
staining. Original magnification, ×350. d CD34 immunoperoxidase
staining highlights the intravascular lymphoma cells from diffuse
lymphomatous infiltration of lymph node parenchyma. Arrows show
sinusoidal cell lining, case 2. Original magnification, ×400. e Medium
power field of the affected BM. The tumor cells diffusely infiltrated in
the cords of BM, case 6. Original magnification, ×100. f Perisplenic
adipose tissue. Note the intravascular infiltrate of large lymphoma cells,
case 4 HE staining. Original magnification, ×150
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negative for smIgD, which is unusual for SMZL cells [19, 20].
Although four of the six patients (nos. 1–4) showed complex
chromosomal aberrations, none of them had trisomy 3 or
allelic loss of 7q21-32, which is usually observed with
SMZL [21, 22]. Clinically, autoimmune phenomena and the
presence of M-protein have been frequently observed in
SMZL patients [17, 20, 23–25], but these were not observed
in our cases. Therefore, our cases are not likely to be
associated with SMZL transformation.
Therefore, these four patients (nos. 1–4) were diagnosed
with de novo CD5-positive DLBCL [26]. Two of these
patients with complex chromosomal aberration had chro-
mosome abnormalities involving 3q27 (no. 2) and 11q13
(no. 4), which have been previously reported in CD5-
positive DLBCL [27]. Yamagichi et al. [28] recently
reported four morphological variants of de novo CD5-
positive DLBCL. Using the molecular classification system
by Hans et al. [29], lymphoma cells of 82% of the patients
were of the non-germinal center B-cell type and the others
were germinal center B-cell type. Interestingly, intravascu-
lar and/or intrasinusoidal lymphomatous infiltration was
observed in 38% of the cells. Although data were not
shown, the bone marrow, liver, and spleen were reported to
be the most frequently involved anatomical sites. De novo
CD5-positive DLBCL is heterogeneous in morphological,
molecular, and clinical aspects. A potion of the cases with
de novo CD5-positive DLBCL with splenomegaly may be
DLBCLRP. While lymphoma cells of two other patients
(nos. 5 and 6) in this study were CD5 negative, clinico-
pathological features other than CD5 were identical in these
six patients (Table 7).
This high rate of CD5-positive lymphoma cells may be
an aberrant expression of the aggressive lymphoma cells
[30–32]. In previous genetic studies, it was suggested
that de novo CD5-positive DLBCL originates from somat-
ically mutated CD5 progenitor B cells [33, 34]. The
mechanism of expression of CD5 in this lymphoma remains
unsolved.
The lymphoma cells positive for CD10 in two patients
(nos. 3 and 6) were considered germinal center B-cell type.
Of the remaining four patients that were negative for CD10,
three were negative for bcl-6 (nos. 1, 4, and 5) and one was
positive for bcl-6 and MUM1 (no. 2). Therefore, later these
were considered non-germinal center B-cell type (Table 3)
[29]. Clinicopathological features were not clearly distin-
guishable among patients with germinal center B-cell-like
DLBCL and those with non-germinal center B-cell-type
DLBCL, except for the appearance of the lymphoma cells
in the peripheral blood. However, our limited sample size
makes it difficult to regard this feature as significant.















Patient 1 + + Weak+ − − + − − 20 − − M-κ + −
Patient 2 + + + − − + − + 20 + − κ na na
Patient 3 + + − + − + − + 30 − − λ + −
Patient 4 + + + − − + − − 10 − − M-λ + −
Patient 5 + na − − − + − − 80 − − na + −
Patient 6 + − − + − + − − 20 + − na + −
FCM flow cytometry, IHC immunohistochemistry, ISH in situ hybridization, smIg surface membrane immunoglobulin
Table 4 Chromosomal analysis of DLBCLRP
Patient
1
47, XY, der(1)del(1)(p?)dup(1)(q25q32), add(6)(q21), der(9)add(9)(p13)add(9)(q34), add(10)(q26),+16,−19,+r 20/20
Patient
2






48,X, −Y, add(2)(p23), del(6)(q?), +add(7)(q11), add(7)(q22)x2, +11, +add(18)(q21) 20/20
Patient
4
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DLBCLRP is a clinically highly aggressive lymphoma
compared with conventional CD5-negative DLBCL and de
novo CD5-positive DLBCL. The patients with de novo CD5-
positive DLBCL showed more aggressive clinical features
and parameters (LDH level, clinical stage, and international
prognostic index (IPI) score) than those with CD5-negative
DLBCL [26]. All six patients in this study had fever, high
LDH levels, clinical stage 4B, and a high-risk IPI score.
Another characteristic feature of DLBCLRP is hemopha-
gocytosis of normal histiocytes observed in all the BMs
(intensive cases; 1/5, 20%) and spleens (intensive cases; 2/6,
33%). This might be due to the high cytokine concentrations
produced by these aggressive lymphoma cells [35]. But none
fulfilled the criteria for adult hemophagocytic syndrome
[36–38]. Moreover, the frequent presence of B symptoms
(14/15) was a characteristic of DLBCLRP. On the basis of
these clinicopathological features, we propose that
DLBCLRP is a distinct clinicopathological entity.
The clinicopathological features of the cases of the Asian
variant of IVL (AIVL) with splenomegaly are similar to
those of DLBCLRP. Splenectomy samples from two
patients with AIVL had cut surfaces that were beef red in
color and there was a diffuse, large, B-cell lymphoma cell
infiltrate in the red pulp [14]. However, the international
consensus meeting of intravascular large B-cell lymphoma
(IVLBCL) proposed a new definition of IVLBCL, which
included cases from both western and Asian countries [39].
They added the criterion of a concomitant minimal
extravascular location of the neoplastic cells [40] to the
WHO criteria, which states that the neoplastic lymphocytes
might only be present in the lumina of the small vessels,
such as capillaries [41]. DLBCLRP produced interstitial
infiltration as well as intrasinusoidal lymphomatous infil-
tration in the BM, liver, and LN (Fig. 2d and Table 5). The
infiltration of DLBCLRP lymphoma cells into the liver and
BM was a more characteristic feature of the SMZL than
AIVL. However, further studies are required to clarify these
relationships.
Briefly, DLBCLRP is an aggressive lymphoma with B
symptoms. During the early phase, it spreads to the liver
and/or BM via intrasinusoidal and/or interstitial infiltration.
Because our characterization of DLBCLRP was based on
the observations of a limited number of patients, further
studies are required to confirm that DLBCLRP is a distinct
clinicopathologic entity.
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Table 5 Summary of the clinical findings DLBCLRP including our
cases [4–13]
Age distribution (years) 40–81 (median 64.5)
Male/female 18:6
B symptom 14/15 (93%)
Weight of the spleen (g) (19 cases) 220–2,600
(median 1,300)
Appearance of tumor cells in peripheral blood 10/23 (43%)
Bone marrow involvement 13/20 (65%)
Liver involvement 11/17 (65%)
Lymph node involvement
Splenic hilus 5/16 (31%)
Abdominal 6/21 (29%)
Other 4/21 (19%)
Systemic lymph node involvement 0/21 (0%)
Table 6 Summary of pathological and phenotypic findings [4–13]
Pattern of splenic infiltration
Splenic sinus 14/19 (74%)
Splenic cord 23/24 (96%)
Pattern of liver infiltration
Intrasinusoidal 8/8 (100%)
Portal area 7/8 (88%)
Pattern of bone marrow infiltration
Intrasinusoidal 3/7 (43%)
Interstitial 10/11 (91%)
Hemophagocytosis in spleen 11/12 (92%)





B-cell marker 24/24 24/24 (100%)
CD5 (FCM) 8/10 (80%)
CD5 (IHC) 3/12 (25%)
CD10 (IHC) 4/14 (29%)
Table 7 Clinicopathological characteristics of DLBCLRP
Lymphoma cells infiltrate diffusely and non-cohesively in the cords of
splenic red pulp
Lymphoma cells frequently involve the bone marrow and the liver at
presentation
Lymph node involvement is rare and limited to the local area, and
lymph node swelling is not significant. Systemic lymph node
swelling is not observed even in the terminal phase of the disease.
Intrasinusoidal as well as interstitial lymphomatous infiltration is
observed in involved tissues
Lymphoma cells are often found in the peripheral blood
Lymphoma cells frequently express surface CD5 antigen
Hemophagocytosis of normal histiocytes is observed in the bone
marrow and the splenic red pulp
508 Virchows Arch (2008) 453:501–509
References
1. Mann RB (1999) Are there site-specific differences among extranodal
aggressive B-cell neoplasms? Am J Clin Pathol 111:S144–S150
2. Harris NL, Aisenberg AC, Meyer JE et al (1984) Diffuse large cell
(histiocytic) lymphoma of the spleen. Clinical and pathologic
characteristics of ten cases. Cancer 54:2460–2467
3. Burke JS (1981) Surgical pathology of the spleen: an approach to
the differential diagnosis of splenic lymphomas and leukemias.
Part II. Diseases of the red pulp. Am J Surg Pathol 5:681–694
4. Kuratsune H, Machii T, Aozasa K et al (1988) B cell lymphoma
showing clinicopathological features of malignant histiocytosis.
Acta Haematol 79:94–98
5. Betman HF, Vardiman JW, Lau J (1994) T-cell-rich B-cell
lymphoma of the spleen. Am J Surg Pathol 18:323–324
6. Faravelli A, Gambini S, Perego D et al (1995) Splenic lymphoma:
unusual case with exclusive red pulp involvement. Pathologica
87:692–695
7. Kobrich U, Falk S, Karhoff M et al (1992) Primary large cell
lymphoma of the splenic sinuses: a variant of angiotrophic B-cell
lymphoma (neoplatic angioendotheliomatosis)? Hum Pathol
2:1184–1187
8. Kroft SH, Howard MS, Picker LJ et al (2000) De novo CD5+ diffuse
large B-cell lymphomas. A heterogeneous group containing an
unusual form of splenic lymphoma. Am J Clin Pathol 114:523–533
9. Mollejo M, Algara P, Mateo MS et al (2003) Large B-cell
lymphoma presenting in the spleen: identification of different
clinicopathologic conditions. Am J Surg Pathol 27:895–902
10. Morice WG, Rodriguez FJ, Hoyer JD et al (2005) Diffuse large B-
cell lymphoma with distinctive patterns of splenic and bone
marrow involvement: clinicopathologic features of two cases.
Mod Pathol 18:495–502
11. Palutke M, Eisenberg L, Narang S et al (1988) B lymphocytic
lymphoma (large cell) of possible splenic marginal zone origin
presenting with prominent splenomegaly and unusual cordal red
pulp distribution. Cancer 62:593–600
12. Salgado C, Feliu E, Montserrat E et al (1993) B-type large-cell
primary splenic lymphoma with massive involvement of the red
pulp. Acta Haematol 89:46–49
13. Stroup RM, Burke JS, Sheibani K et al (1992) Splenic involvement
by aggressive malignant lymphomas of B-cell and T-cell types. A
morphologic and immunophenotypic study. Cancer 69:413–420
14. Murase T, Nakamura S, Tashiro K et al (1997) Malignant
histiocytosis-like B-cell lymphoma, a distinct pathologic variant
of intravascular lymphomatosis: a report of five cases and review
of the literature. Br J Haematol 99:656–664
15. Hashimoto K, Miura I, Chyubachi A et al (1995) Correlations of
chromosome abnormalities with histologic and immunologic
characteristics in 49 patients from Akita, Japan with non-Hodgkin
lymphoma. Cancer Genet Cytogenet 81:56–65
16. Mitelman F (ed) ISCN (1995). An international system for human
cytogenetic nomenclature. Karger, Basel
17. Berger F, Felman P, Thieblemont C et al (2000) Non-MALT
marginal zone B-cell lymphomas: a description of clinical
presentation and outcome in 124 patients. Blood 95:1950–1956
18. Camacho FI, Mollejo M, Mateo MS et al (2001) Progression to
large B-cell lymphoma in splenic marginal zone lymphoma: a
description of a series of 12 cases. Am J Surg Pathol 25:1268–1276
19. Mollejo M, Menárguez J, Lloret E, Sánchez A, Campo E, Algara P,
Cristóbal E, Sánchez E, Piris MA (1995) Splenic marginal zone
lymphoma: a distinctive type of low-grade B-cell lymphoma. A
clinicopathological study of 13 cases. Am J Surg Pathol 19:1146–1157
20. Van Huyen JP, Molina T, Delmer A et al (2000) Splenic marginal
zone lymphoma with or without plasmacytic differentiation. Am J
Surg Pathol 24:1581–1592
21. Dierlamm J, Michaux L, Wlodarska I et al (1996) Trisomy 3 in
marginal zone B-cell lymphoma: a study based on cytogenetic
analysis and fluorescence in situ hybridization. Br J Haematol
93:242–249
22. Mateo M, Mollejo M, Villuendas R et al (1999) 7q31-32 allelic
loss is a frequent finding in splenic marginal zone lymphoma. Am
J Pathol 154:1583–1589
23. Chacón JI, Mollejo M, Muñoz E et al (2002) Splenic marginal
zone lymphoma: clinical characteristics and prognostic factors in a
series of 60 patients. Blood 100:1648–1654
24. Franco V, Florena AM, Iannitto E (2003) Splenic marginal zone
lymphoma. Blood 101:2464–2472
25. Iannitto E, Ambrosetti A, Ammatuna E et al (2004) Splenic
marginal zone lymphoma with or without villous lymphocytes.
Hematologic findings and outcomes in a series of 57 patients.
Cancer 101:2050–2057
26. Yamaguchi M, Seto M, Okamoto M et al (2002) De novo CD5+
diffuse large B-cell lymphoma: a clinicopathologic study of 109
patients. Blood 99:815–821
27. Yoshioka T, Miura I, Kume M et al (2005) Cytogenetic features of de
novo CD5-positive diffuse large B-cell lymphoma: chromosome
aberrations affecting 8p21 and 11q13 constitute major subgroups with
different overall survival. Genes Chromosomes Cancer 42:149–157
28. Yamaguchi M, Nakamura N, Suzuki R et al (2008) De novo CD5+
diffuse large B-cell lymphoma: results of a detailed clinicopatho-
logical review in 120 patients. Haematologica 93(8):1195–1202
29. Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of
the molecular classification of diffuse large B-cell lymphoma by
immunohistochemistry using a tissue microarray. Blood 103:275–282
30. Ballesteros E, Osborne BM, Matsushima AY (1998) CD5+ low-
grade marginal zone B-cell lymphomas with localized presentation.
Am J Surg Pathol 22:201–207
31. Ferry JA, Yang WI, Zukerberg LR et al (1996) CD5+ extranodal
marginal zone B-cell (MALT) lymphoma. A low grade neoplasm
with a propensity for bone marrow involvement and relapse.. Am
J Clin Pathol 105:31–37
32. Tiesinga JJ, Wu CD, Inghirami C (2000) CD5+ follicle center
lymphoma. immunophenotyping detects a unique subset of
“floral” follicular lymphoma. Am J Clin Pathol 114:912–921
33. Katzenberger T, Lohr A, Schwarz S et al (2003) Genetic analysis of de
novo CD5+ diffuse large B-cell lymphomas suggests an origin from a
somatically mutated CD5+ progenitor B cell. Blood 101:699–702
34. Nakamura N, Hashimoto Y, Kuze T et al (1999) Analysis of the
immunoglobulin heavy chain gene variable region of CD5-
positive diffuse large B-cell lymphoma. Lab Invest 79:925–933
35. Imashuku S (1997) Differential diagnosis of hemophagocytic
syndrome: underlying disorders and selection of the most effective
treatment. Int J Hematol 66:135–151
36. Tsuda H (1997) Hemophagocytic syndrome in children and
adults. Int J Hematol 65:215–226
37. Wong KF, Chan JK (1992) Reactive hemophagocytic syndrome—
a clinicopathologic study of 40 patients in an Oriental population.
Am J Med 93:177–180
38. Yao M, Cheng AL, Su IJ et al (1994) Clinicopathological spectrum
of hemophagocytic syndrome in Epstein–Barr virus associated
peripheral T-cell lymphoma. Br J Haematol 87:535–543
39. Ponzoni M, Ferreri AJ, Campo E et al (2007) Definition, diagnosis,
and management of intravascular large B-cell lymphoma: proposals
and perspectives from an international consensus meeting. J Clin
Oncol 25:3168–3173
40. Ponzoni M, Arrigoni G, Gould VE et al (2000) Lack of CD 29
(beta1 integrin) and CD 54 (ICAM-1) adhesion molecules in
intravascular lymphomatosis. Hum Pathol 31:220–226
41. Gatter KC, Warnke RA (2001) Intravascular large B-cell
lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds)
Tumors of haematopoietic and lymphoid tissues. IARC, Lyon
Virchows Arch (2008) 453:501–509 509
